Please login to the form below

Not currently logged in
Email:
Password:

UK launch of RebiDose for treatment of MS

Merck Serono has launched the UK's first pre-filled, single-use disposable pen for the self-administration of Rebif

Merck's division for innovative prescription pharmaceuticals, Merck Serono, has launched the UK's first pre-filled, single-use disposable pen for the self-administration of Rebif, a disease-modifying drug for the treatment of relapsing forms of multiple sclerosis (MS).

The RebiDose device is a pre-filled, pre-loaded, single-use disposable pen and is the first and only injection delivery device that needs no assembly or priming by the patient.

According to MS nurse specialist at Herefordshire PCT, Del Thomas: "The simplicity of the RebiDose pen may be ideal for those patients with MS who have significant cognitive, visual or dexterity impairment. The needle is hidden and the rubber grips can maximise control by the patient throughout the entire injection process."

RebiDose pens are available in strengths of 22mcg and 44mcg as well as the titration pack for initiation of treatment. Each pen can be stored in the fridge for up to 18 months, and at room temperature of up to 25 degrees for a single period of 14 days, giving patients flexibility with storage conditions when travelling. 

RebiDose has been approved in the EU. While the UK was the first to launch RebiDose, other European countries are expected to follow shortly.

3rd November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics